Infraredx, a Nipro Company

Bringing you the best tools available: the Makoto™ Imaging System & OKAY®II Y-Connector.

The PROSPECT II Study is now published in The Lancet!

[Dr. Todd C. Villines @ToddVillinesMD]

🌟🌟Coronary artery disease: a BIG movement to change from reactive end-stage treatment to early detection and treatment: https://t.co/xyqwuEDHFR

Kudos to the The Lancet Commission for actively studying the global health benefits of this paradigm shift from "ischemic" heart disease to atherosclerosis!🌟🌟

[Millbrook Medical Conferences @MillbrookMed]

This afternoon at Imperial #VPM2025 featured a keynote from @rallamee: Rethinking Coronary Artery Disease: It's All About the Plaque

We also enjoyed sessions on angiography-derived physiology and shear stress, as well as novel intramuscular imaging technologies

We’re over halfway through Imperial #VPM2025. Don’t be sad, we’re back tomorrow for the third and final day!

[Prof. Hector M. Garcia-Garcia @hect2701]

#VPM2025
#Lp(a) elevation attenuates reduction of plaque size in an #alirocumab study

@Ortega_Paz @sbrugaletta @sjorge4 @TCTMD @TCTConference @PCRonline @CRT_meeting @news_hart @EuroInterventio @GTCardFellows @RaberLorenz

[NIPRO Group @Nipro_group]

🎤 Innovation Spotlight at NCVH 2025 🎤 A sincere thank you to Dr. Craig Walker for his outstanding presentation on Aperta, the new focal force balloon technology, at this year’s NCVH conference in New Orleans.

#NCVH2025 #InterventionalCardiology #wearenipro

[NIPRO Group @Nipro_group]

The energy in Paris is real. #EuroPCR is underway and we’re right in the middle of it all.

Booth M23. Big innovations. Even bigger passion.

If you’re here, come say hi.

👉 https://t.co/2BxKZOt3xm

#TeamNipro #InterventionalCardiology #MedTech #ParisVibes

[NIPRO Group @Nipro_group]

📍 Location: SCAI Engagement Center in the Exhibit Hall
🗓️ Dates & Times:
• May 1st: 8:15 AM – 12:00 PM & 1:15 PM – 7:00 PM
• May 2nd: 8:15 AM – 12:15 PM & 1:25 PM – 5:30 PM
• May 3rd: 8:00 AM – 11:45 AM

✨ No appointment needed – just bring your smile and stop by!

[NIPRO Group @Nipro_group]

India’s first Makoto has arrived at Manipal Hospital! 🎉 Huge thanks to RamanPandurangan for his support! #wearenipro #InterventionalCardiology #CardiacCare #HealthcareTechnology

[NIPRO Group @Nipro_group]

📍 Location: SCAI Engagement Center in the Exhibit Hall
🗓️ Dates & Times:
• May 1st: 8:15 AM – 12:00 PM & 1:15 PM – 7:00 PM
• May 2nd: 8:15 AM – 12:15 PM & 1:25 PM – 5:30 PM
• May 3rd: 8:00 AM – 11:45 AM

✨ No appointment needed – just bring your smile and stop by!

[Infraredx, a Nipro Company @infraredx]

🎉 We’re excited to announce Nozomu "Fuji" Fujita’s promotion to Exec. Officer, Nipro Corp, & Steve Sum, PhD, as our new President & CEO! Fuji will continue driving our vision, while Steve leads us into a new era of innovation. Join us in celebrating their success! 🚀

[Infraredx, a Nipro Company @infraredx]

Join us for the #NIRS Conference on Wednesday, November 13th at 19:00-20:30 JST. Register for the free event by scanning the QR code above or clicking this link: https://t.co/D5nYlLOrYq
Speakers include Dr. Hiroki Saito, Dr. Takahide Suzuki, and Dr. Nobuaki Suzuki.

[Poonam Velagapudi @Pooh_Velagapudi]

HF-OCT total vessel imaging in heart Tx patients—>low catheter profile, lower contrast amount, ideal IVI for OHT?

Dr. Hiram Bezerra #TCT2024 @crfheart #IVI #OCT #ACCIC

[NIPRO Group @Nipro_group]

Sharpen your image interpretation skills during one of the fifteen Image Interpretation Training workshops during #TCT2024.

Don’t miss an opportunity to learn from the experts and see case examples with Gentuity HF-OCT.

Test your knowledge, and add your answer in the comments!

#IntravascularImaging #OCT #InterventionalCardiology #CRF

[NIPRO Group @Nipro_group]

Looking to fine-tune your Image Interpretation skills? You’re in luck! Join us at TCT in Washington, DC this year.

Hands on training sessions are taking place Monday, Tuesday and Wednesday, find the one that best fits your schedule.

#TCT2024 #imaging #imageinterpretation #IVUS #NIRS @crfheart @tctconference @esc_journals

[NIPRO Group @Nipro_group]

Exciting news! 🎉 Gentuity, LLC’s HF-OCT Imaging System has officially received FDA clearance for pre- and post-coronary interventions.

This milestone underscores the advanced capabilities of our system, offering clinicians a reliable tool for pre-PCI imaging to inform treatment decisions better and enhance patient care outcomes. 🚀

We are proud of our team’s hard work and looking forward to seeing the positive impact this will have on cardiac care! ❤️

#MedicalInnovation #FDAApproval #Cardiolology #HealthcareTechnology #PatientCare #OCTImaging #PCI #WeAreNipro

[OPCI @OPCILive]

Join Nipro in partnership with OPCI at our September 28th Hands-on Workshop! Gain proficiency in advanced intravascular imaging guidance techniques in complex pci. Open to all ICs and fellows. Register at https://t.co/mmlOPsp3bL @infraredx

[Sunil E. Saith, MD, MPH, FACP @s7saith]

Question re #IVUS: Angiography shows a high thrombotic, eccentric mid LAD lesion w/TIMI-3 flow...to better characterize the lesion, would you pass an IVUS catheter to better define it or would fear of dislodging thrombus preclude IVUS use? @ziadalinyc @ESHLOF

[New Cardiovascular Horizons @NCVHonline]

Live case with Dr. Matthew Finn at the @CardioInstitute ASC in Gray, LA. #ncvh2024

[Dr Thomas Keeble @DrKeeble]

Fantastic session on the current and future use of @infraredx NIRS IVUS. Nodules, DCB, and future therapies. Including the @EssexCTC and @KingsCollegeLon NIRS IVUS registry. @DrNileshPareek @Dizzledavies73 @dr_skhan1 @MSEResearchTeam @MTRC_ARU @MSEHospitals

[Yoichiro.S@循環器内科医 @cardio_dr_ys]

Congratulations 🎉
We are standing on the dawn of an era where new therapeutic strategies are being implemented. I express my respect to the authors who have led to such remarkable outcomes.

[Duk-Woo Park @dukwoo_park]

A long-waited PREVENT trial is now presented at LBCT-V #ACC2024
🇰🇷From the inception of trial to completion of trial took a decade.
✅1,606 pts with intracoronary imaging-detected “Vulnerable Plaque” randomized 1:1 to (1) Preventive PCI vs (2) OMT alone.
✅Prevent PCI significantly reduce primary composite endpoint (CV death, TV-MI, TVR, hospitalization for UA) at 2 yr. The effect of Preventive PCI was sustained up to 7 years.
✅First RCT shows that Preventive PCI is effective for non-flow limiting vulnerable atherosclerosis coronary plaque.
✅We believe that PREVENT would be one of the seminal investigations in the history of PCI.
@dukwoo_park @GreggWStone @JungMinAhn5 @DFCapodanno @djc795 @TheLancet
Further details:
https://t.co/R2NJ0dsdML